CY2013029PI2 - NEW INSULIN DERIVATIVES - Google Patents

NEW INSULIN DERIVATIVES

Info

Publication number: CY2013029PI2
Authority: CY; Cyprus
Prior art keywords: insulin derivatives; new insulin; new; derivatives; insulin
Prior art date: 2003-08-05

Application number

CY2013029C

Other languages

Greek (el)

Original Assignee

Novo Nordisk A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-05

Filing date

2013-07-08

Publication date

2015-11-04

2013-07-08 Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S

2015-11-04 Publication of CY2013029PI2 publication Critical patent/CY2013029PI2/en

2015-11-04 Publication of CY2013029PI1 publication Critical patent/CY2013029PI1/en

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CY2013029C 2003-08-05 2013-07-08 NEW INSULIN DERIVATIVES CY2013029PI1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200301129		2003-08-05
US49545103P	2003-08-14	2003-08-14
EP04739008A EP1660531A2 (en)	2003-08-05	2004-07-22	Novel insulin derivatives

Publications (2)

Publication Number	Publication Date
CY2013029PI2 true CY2013029PI2 (en)	2015-11-04
CY2013029PI1 CY2013029PI1 (en)	2015-11-04

Family

ID=34117520

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (en)	2003-08-05	2013-03-28	NEW INSULIN PRODUCERS
CY2013027C CY2013027PI1 (en)	2003-08-05	2013-07-04	NEW INSULIN DERIVATIVES
CY2013029C CY2013029PI1 (en)	2003-08-05	2013-07-08	NEW INSULIN DERIVATIVES
CY2013029C CY2013029I2 (en)	2003-08-05	2023-12-28	NEW INSULIN DERIVATIVES
CY2013027C CY2013027I1 (en)	2003-08-05	2024-01-31	NEW INSULIN DERIVATIVES

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (en)	2003-08-05	2013-03-28	NEW INSULIN PRODUCERS
CY2013027C CY2013027PI1 (en)	2003-08-05	2013-07-04	NEW INSULIN DERIVATIVES

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CY2013029C CY2013029I2 (en)	2003-08-05	2023-12-28	NEW INSULIN DERIVATIVES
CY2013027C CY2013027I1 (en)	2003-08-05	2024-01-31	NEW INSULIN DERIVATIVES

Country Status (18)

Country	Link
US (3)	US7615532B2 (en)
EP (3)	EP1660531A2 (en)
JP (1)	JP4463814B2 (en)
KR (1)	KR101159559B1 (en)
AU (2)	AU2004261353B2 (en)
BE (2)	BE2013C035I2 (en)
BR (1)	BRPI0413276B8 (en)
CA (1)	CA2531988C (en)
CY (5)	CY1113850T1 (en)
FR (2)	FR13C0035I2 (en)
HU (1)	HUS1300033I1 (en)
IL (1)	IL172980A (en)
LU (2)	LU92213I2 (en)
MX (1)	MXPA06001283A (en)
NO (5)	NO340925B1 (en)
PL (1)	PL2107069T3 (en)
RU (1)	RU2518460C2 (en)
WO (1)	WO2005012347A2 (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602004021603D1 (en) *	2003-07-25	2009-07-30	Conjuchem Biotechnologies Inc	INSULIN DERIVATIVES WITH LONG-LASTING EFFECT AND METHOD FOR THE PRODUCTION THEREOF
MXPA06001283A (en) *	2003-08-05	2006-04-11	Novo Nordisk As	Novel insulin derivatives.
WO2006082204A1 (en) *	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
EP1846447B1 (en) *	2005-02-02	2013-08-21	Novo Nordisk A/S	Insulin derivatives
JP4808785B2 (en)	2005-12-28	2011-11-02	ノボ・ノルデイスク・エー／エス	Insulin composition and method for producing the composition
EP1991576B1 (en)	2006-02-27	2010-09-29	Novo Nordisk A/S	Insulin derivatives
WO2007104736A2 (en) *	2006-03-13	2007-09-20	Novo Nordisk A/S	Acylated single chain insulin
US8293965B2 (en)	2006-04-28	2012-10-23	Kimberly-Clark Worldwide, Inc.	Antimicrobial site dressings
EP2024390B1 (en)	2006-05-09	2015-08-19	Novo Nordisk A/S	Insulin derivative
CN101437849B (en) *	2006-05-09	2015-09-30	诺沃-诺迪斯克有限公司	Insulin derivatives
MX2008014061A (en) *	2006-05-09	2008-11-14	Novo Nordisk As	Insulin derivative.
JP5097900B2 (en) *	2006-06-27	2012-12-12	独立行政法人物質・材料研究機構	Method for producing active ester of organic acid or derivative thereof
ES2542146T3 (en)	2006-07-31	2015-07-31	Novo Nordisk A/S	PEGylated extended insulin.
DK2074141T3 (en)	2006-09-22	2016-11-28	Novo Nordisk As	The protease resistant insulin analogues.
US9387176B2 (en)	2007-04-30	2016-07-12	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US20110144010A1 (en)	2007-06-01	2011-06-16	Novo Nordisk A/S	Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
AU2008257505B2 (en) *	2007-06-01	2013-05-16	Novo Nordisk A/S	Stable non-aqueous pharmaceutical compositions
US9034818B2 (en)	2007-06-13	2015-05-19	Novo Nordisk A/S	Pharmaceutical formulations comprising an insulin derivative
KR20100053561A (en) *	2007-08-15	2010-05-20	노보 노르디스크 에이/에스	Insulin analogues with an acyl and alkylene glycol moiety
EP2178910B1 (en) *	2007-08-15	2014-10-08	Novo Nordisk A/S	Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
CN101157725B (en) *	2007-10-24	2012-07-25	中国药科大学	Preparation method of human insulin analogue and usage thereof
US8710000B2 (en)	2007-11-08	2014-04-29	Novo Nordisk A/S	Insulin derivative
JP5241849B2 (en)	2007-11-16	2013-07-17	ノボ・ノルデイスク・エー／エス	Pharmaceutical composition comprising insulin and insulinotropic peptide
WO2009112583A2 (en)	2008-03-14	2009-09-17	Novo Nordisk A/S	Protease-stabilized insulin analogues
CN102037008B (en)	2008-03-18	2016-08-31	诺沃-诺迪斯克有限公司	Protease-stabilized, acylated insulin analogs
US8637647B2 (en)	2008-09-12	2014-01-28	Novo Nordisk A/S	Method of acylating a peptide or protein
AU2009309623B9 (en) *	2008-10-30	2014-10-02	Novo Nordisk A/S	Treating diabetes melitus using insulin injections with less than daily injection frequency
BRPI1007313A2 (en)	2009-01-23	2016-02-10	Novo Nordisk As	fgf21 derivatives with a-b-c-d-e albumin ligand and their use.
WO2011051312A1 (en)	2009-10-30	2011-05-05	Novo Nordisk A/S	Derivatives of cgrp
CA2786953A1 (en)	2010-01-12	2011-07-21	Florian Anders Foeger	Pharmaceutical compositions for oral administration of insulin peptides
EP2536434B1 (en)	2010-02-16	2016-04-20	Novo Nordisk A/S	Purification method
JP5826772B2 (en)	2010-02-16	2015-12-02	ノヴォノルディスクアー／エス	Conjugate protein
US20130143803A1 (en)	2010-05-10	2013-06-06	Novo Nordisk A/S	Process for the Preparation of Insulin-Zinc Complexes
WO2011146973A1 (en)	2010-05-25	2011-12-01	Monash University	Insulin analogues
CN102933599A (en)	2010-06-23	2013-02-13	诺沃—诺迪斯克有限公司	Human insulin containing additional disulfide bonds
EP2585484A1 (en)	2010-06-23	2013-05-01	Novo Nordisk A/S	Insulin analogues containing additional disulfide bonds
RU2598273C2 (en) *	2010-06-23	2016-09-20	Ново Нордиск А/С	Insulin derivatives containing additional disulfide bonds
JP2013540771A (en)	2010-10-15	2013-11-07	ノヴォノルディスクアー／エス	Novel N-terminally modified insulin derivative
CN103167878A (en) *	2010-10-27	2013-06-19	诺沃—诺迪斯克有限公司	Treating diabetes melitus using insulin injections administered with varying injection intervals
DK2632478T3 (en)	2010-10-27	2019-10-07	Novo Nordisk As	TREATMENT OF DIABETES MELITUS USING INSULIN INJECTIONS SUBMITTED AT VARIOUS INJECTION INTERVALS
JP2013545782A (en)	2010-12-14	2013-12-26	ノヴォノルディスクアー／エス	Fast-acting insulin combined with long-acting insulin
CN103370075A (en)	2011-02-15	2013-10-23	诺沃—诺迪斯克有限公司	Long-acting IL-1 receptor antagonists
JP2014510739A (en) *	2011-03-28	2014-05-01	ノヴォノルディスクアー／エス	New glucagon analogues
WO2012140155A1 (en)	2011-04-14	2012-10-18	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
CN103596584B (en)	2011-06-15	2016-12-14	诺沃—诺迪斯克有限公司	Polysubstituted insulin
RU2610175C2 (en)	2011-09-23	2017-02-08	Ново Нордиск А/С	Novel glucagon analogues
RU2014127270A (en) *	2011-12-15	2016-02-10	Шанхай Хэнжуй Фармасьютикал Ко., Лтд.	ANALOGUE OF HUMAN INSULIN AND ITS Acylated Derivative
US20140357838A1 (en)	2011-12-21	2014-12-04	Novo Nordisk A/S	N-Terminally Modified Insulin Derivatives
US9481721B2 (en)	2012-04-11	2016-11-01	Novo Nordisk A/S	Insulin formulations
US20160031962A1 (en) *	2012-04-20	2016-02-04	Kleomenis K. Barlos	Solid phase peptide synthesis of insulin using side chain achored lysine
CA2872083A1 (en)	2012-05-01	2013-11-07	Novo Nordisk A/S	Pharmaceutical composition
US20150111820A1 (en)	2012-07-09	2015-04-23	Novo Nordisk A/S	Novel use of insulin derivatives
UA116217C2 (en)	2012-10-09	2018-02-26	Санофі	Exendin-4 derivatives as dual glp1/glucagon agonists
WO2014060447A1 (en)	2012-10-17	2014-04-24	Novo Nordisk A/S	Fatty acid acylated d-amino acids for oral peptide delivery
HK1211232A1 (en)	2012-12-21	2016-05-20	Sanofi	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
JP6755175B2 (en) *	2013-03-20	2020-09-16	ノヴォノルディスクアー／エス	Insulin medication regimen
SI2986313T1 (en)	2013-04-18	2019-09-30	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP2016519127A (en)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	New dosing regimen
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
AU2014333979B2 (en)	2013-10-07	2018-02-15	Novo Nordisk A/S	Novel derivative of an insulin analogue
FR3013049B1 (en)	2013-11-14	2015-11-13	You-Ping Chan	ANALOGUE OF INSULIN GLARGINE
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
TW201609799A (en)	2013-12-13	2016-03-16	賽諾菲公司	Dual GLP-1/GIP receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015124612A1 (en)	2014-02-18	2015-08-27	Novo Nordisk A/S	Stable glucagon analogues and use for treatment of hypoglycaemia
AR099569A1 (en)	2014-02-28	2016-08-03	Novo Nordisk As	INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
TW201625670A (en)	2014-04-07	2016-07-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en)	2014-04-07	2016-07-16	賽諾菲公司	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en)	2014-04-07	2016-07-16	賽諾菲公司	Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en)	2015-06-05	2017-09-27	Sanofi Sa	PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en)	2015-07-10	2017-09-20	Sanofi Sa	DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
EP3341401A1 (en)	2015-08-25	2018-07-04	Novo Nordisk A/S	Novel insulin derivatives and the medical uses hereof
JP2018531899A (en)	2015-08-25	2018-11-01	ノヴォノルディスクアー／エス	Novel insulin derivatives and their medical use
JP7432361B2 (en) *	2016-08-02	2024-02-16	江蘇恒瑞医薬股▲ふん▼有限公司	Acylated derivatives of human insulin or its analogs
WO2018096162A1 (en)	2016-11-28	2018-05-31	Novo Nordisk A/S	Insulin degludec in cardiovascular conditions
MA46890A (en)	2016-11-28	2021-04-28	Novo Nordisk As	INSULIN DEGLUDEC FOR IMPROVEMENT OF GLYCEMIC CONTROL AND REDUCTION OF COMPLICATIONS OF ACUTE AND LONG-TERM DIABETES
WO2018096164A1 (en)	2016-11-28	2018-05-31	Novo Nordisk A/S	Insulin degludec for treating diabetes
TWI700091B (en)	2016-12-16	2020-08-01	丹麥商諾佛儂迪克股份有限公司	Insulin containing pharmaceutical compositions
JOP20190273A1 (en) *	2017-05-26	2019-11-24	Lilly Co Eli	Insulin treated with basil complex
US20210032307A1 (en)	2018-02-09	2021-02-04	Jiangsu Hengrui Medicine Co., Ltd.	Codon optimized precursor gene and signal peptide gene of human insulin analogue
KR20210016400A (en)	2018-05-24	2021-02-15	지앙수 헨그루이 메디슨 컴퍼니 리미티드	Method for producing a precursor of recombinant human insulin or its analog
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
WO2020002428A1 (en)	2018-06-26	2020-01-02	Novo Nordisk A/S	System providing dose recommendations for basal insulin titration
KR102666154B1 (en)	2018-08-08	2024-05-20	주식회사 대웅제약	Long-acting Insulin Analog and Derivatives Thereof
KR20200080747A (en)	2018-12-27	2020-07-07	주식회사 폴루스	An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same
KR20200080748A (en)	2018-12-27	2020-07-07	주식회사 폴루스	A Method for Purifying Proinsulin Using Anion Exchange Chromatography
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
TWI844709B (en)	2019-07-31	2024-06-11	美商美國禮來大藥廠	Relaxin analogs and methods of using the same
AU2020417892A1 (en)	2019-12-30	2022-08-25	Gan & Lee Pharmaceuticals Co., Ltd.	Insulin derivative
AU2021273262A1 (en)	2020-05-15	2022-12-08	Eli Lilly And Company	Extended time action acylated insulin compounds
CN113773398B (en) *	2020-06-10	2023-05-23	宁波鲲鹏生物科技有限公司	De-glu insulin derivative and application thereof
EP4180060A1 (en)	2021-11-15	2023-05-17	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en)	2021-11-15	2025-01-02	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en)	2022-06-30	2024-01-03	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
CN118574842A (en)	2022-01-28	2024-08-30	甘李药业股份有限公司	Acylated insulin
EP4299071A1 (en)	2022-07-01	2024-01-03	Adocia	Compositions comprising a peptide or a protein and an acylated amino acid
US20250154220A1 (en) *	2023-11-15	2025-05-15	Ambio, Inc.	Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1212679B (en)	1957-08-03	1966-03-17	Novo Terapeutisk Labor As	Process for the preparation of insulin solutions
GB1042194A (en)	1962-04-30	1966-09-14	Olin Mathieson	Insulin preparations
US3528960A (en)	1968-10-07	1970-09-15	Lilly Co Eli	N-carboxyaroyl insulins
US3868358A (en)	1971-04-30	1975-02-25	Lilly Co Eli	Protamine-insulin product
GB1492997A (en)	1976-07-21	1977-11-23	Nat Res Dev	Insulin derivatives
JPS5767548A (en)	1980-10-14	1982-04-24	Shionogi & Co Ltd	Insulin analog and its preparation
FI78616C (en)	1982-02-05	1989-09-11	Novo Industri As	Process for preparing an infused stabilized insulin solution having an elevated zinc content
PH25772A (en)	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
NZ222907A (en)	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en)	1987-10-29	1997-02-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Factor VIII formulations in high ionic strength media
US4877608A (en)	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (en)	1988-04-05	1989-10-11	Kodama Kk	Insulin derivative and use thereof
DE3827533A1 (en)	1988-08-13	1990-02-15	Hoechst Ag	PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS
KR910700262A (en)	1988-12-23	1991-03-14	안네 제케르	Human insulin analogues
PT93057B (en)	1989-02-09	1995-12-29	Lilly Co Eli	PROCESS FOR THE PREPARATION OF INSULIN ANALOGS
IT1240314B (en)	1989-09-28	1993-12-07	Immunobiology Research Institutes, Inc.	STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.
JP3122128B2 (en)	1989-12-21	2001-01-09	ノボノルディスクアクティーゼルスカブ	Peptide preparation
DK45590D0 (en)	1990-02-21	1990-02-21	Novo Nordisk As
JP3193398B2 (en)	1991-07-23	2001-07-30	サンデン株式会社	Showcase
DK0618807T3 (en)	1991-12-20	2003-03-03	Novo Nordisk As	Stabilized pharmaceutical formulation comprising human growth hormone and histidine
US6011007A (en)	1993-09-17	2000-01-04	Novo Nordisk A/S	Acylated insulin
CZ287945B6 (en) *	1993-09-17	2001-03-14	Novo Nordisk A/S	Insulin derivative and pharmaceutical preparation in which it is comprised and which is intended for treating diabetes mellitus
US6869930B1 (en)	1993-09-17	2005-03-22	Novo Nordisk A/S	Acylated insulin
US5652216A (en)	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
AU3562195A (en)	1994-10-04	1996-04-26	Novo Nordisk A/S	Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en)	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
US5830999A (en)	1995-01-26	1998-11-03	Regents Of The University Of California	Stabilization of insulin through ligand binding interations
US6251856B1 (en)	1995-03-17	2001-06-26	Novo Nordisk A/S	Insulin derivatives
PL183698B1 (en)	1995-03-17	2002-06-28	Novo Nordisk As	Derivatives of insulin
CA2226575C (en)	1995-07-27	2011-10-18	Genentech, Inc.	Stabile isotonic lyophilized protein formulation
US6451970B1 (en) *	1996-02-21	2002-09-17	Novo Nordisk A/S	Peptide derivatives
US5898267A (en) *	1996-04-10	1999-04-27	Mcdermott; Kevin	Parabolic axial lighting device
US5866538A (en)	1996-06-20	1999-02-02	Novo Nordisk A/S	Insulin preparations containing NaCl
ATE278711T1 (en)	1996-07-11	2004-10-15	Novo Nordisk As	METHOD FOR SELECTIVE ACETYLATION
US5905140A (en)	1996-07-11	1999-05-18	Novo Nordisk A/S, Novo Alle	Selective acylation method
US5763401A (en)	1996-07-12	1998-06-09	Bayer Corporation	Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
DK0821006T3 (en)	1996-07-26	2004-08-16	Aventis Pharma Gmbh	Insulin derivatives with increased zinc binding
IL119029A0 (en)	1996-08-07	1996-11-14	Yeda Res & Dev	Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) *	1997-02-07	1999-04-27	Novo Nordisk A/S	Crystallization of proteins
ATE219942T1 (en)	1997-03-20	2002-07-15	Novo Nordisk As	THERAPEUTIC POWDER FORMULATION FOR PULMONARY USE CONTAINING CRYSTALLINE INSULIN
EP0969860B1 (en)	1997-03-20	2002-07-17	Novo Nordisk A/S	Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
ES2260832T3 (en) *	1997-03-20	2006-11-01	Novo Nordisk A/S	INSULIN CRYSTALS DESPROVISTOS DE ZINC USED IN PULMONARY COMPOSITIONS.
US7097845B2 (en)	1997-04-23	2006-08-29	Jacob Sten Petersen	Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
DK1283051T3 (en)	1997-06-13	2006-10-16	Lilly Co Eli	Stable insulin formulations
US20020155994A1 (en)	1997-10-24	2002-10-24	Svend Havelund	Aggregates of human insulin derivatives
EA200000453A1 (en)	1997-10-24	2000-10-30	Эли Лилли Энд Компани	COMPOSITIONS OF INSOLUBLE INSULIN
CN1240718C (en) *	1997-10-24	2006-02-08	诺沃挪第克公司	Aggregates of human insulin derivatives
US6451762B1 (en)	1997-10-24	2002-09-17	Novo Nordisk A/S	Aggregates of human insulin derivatives
ZA989744B (en)	1997-10-31	2000-04-26	Lilly Co Eli	Method for administering acylated insulin.
US6531448B1 (en)	1997-12-23	2003-03-11	Eli Lilly And Company	Insoluble compositions for controlling blood glucose
EP1044016B1 (en)	1998-01-09	2005-03-16	Novo Nordisk A/S	Stabilised insulin compositions
ES2177323T3 (en)	1998-10-16	2002-12-01	Novo Nordisk As	INSULIN PREPARATIONS CONCENTRATED STABLE FOR THE ADMINISTRATIONPOR VIA PULMONAR.
US6211144B1 (en)	1998-10-16	2001-04-03	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
EP2921180B1 (en)	1999-02-22	2019-08-14	University of Connecticut	Albumin-free factor VIII formulations
AU4450700A (en)	1999-04-27	2000-11-10	Eli Lilly And Company	Insulin crystals for pulmonary administration
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
DE10022092A1 (en)	2000-05-08	2001-11-15	Aventis Behring Gmbh	Stabilized protein preparation and process for its preparation
US6652886B2 (en)	2001-02-16	2003-11-25	Expression Genetics	Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (en)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinc-free and low-zinc insulin preparations with improved stability
AU2002316811A1 (en)	2001-06-28	2003-03-03	Novo Nordisk A/S	Stable formulation of modified glp-1
PL374949A1 (en)	2001-12-20	2005-11-14	Eli Lilly And Company	Insulin molecule having protracted time action
US8003605B2 (en)	2002-03-13	2011-08-23	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
JP5599543B2 (en)	2002-05-07	2014-10-01	ノヴォノルディスクアー／エス	Soluble formulation containing monomeric insulin and acylated insulin
US20050232899A1 (en)	2002-05-31	2005-10-20	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en)	2002-06-20	2004-01-01	Bruce Kerwin	Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (en)	2002-08-23	2006-08-25	(주)헬릭서	Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease
EP1562626B1 (en)	2002-10-29	2007-11-28	ALZA Corporation	Stabilized, solid-state polypeptide particles
US20040138099A1 (en)	2002-11-29	2004-07-15	Draeger Eberhard Kurt	Insulin administration regimens for the treatment of subjects with diabetes
CN101822834A (en)	2003-02-07	2010-09-08	味之素株式会社	Medicine for treating diabetes
CA2787820A1 (en)	2003-02-19	2004-09-02	Novartis Ag	Glycoprotein antigen sima135 expressed in metastatic human tumor cells
EA200501422A1 (en)	2003-03-04	2006-04-28	Дзе Текнолоджи Девелопмент Компани Лтд.	DURABLE INJECTABLE COMPOSITION OF INSULIN AND METHODS OF ITS MANUFACTURE AND APPLICATION
WO2004112828A1 (en)	2003-06-25	2004-12-29	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
US20050054818A1 (en)	2003-07-02	2005-03-10	Brader Mark Laurence	Crystalline compositions for controlling blood glucose
SI2107069T1 (en)	2003-08-05	2013-04-30	Novo Nordisk A/S	Novel insulin derivatives
MXPA06001283A (en)	2003-08-05	2006-04-11	Novo Nordisk As	Novel insulin derivatives.
ES2574581T3 (en)	2003-08-14	2016-06-20	Novo Nordisk Health Care Ag	Aqueous liquid pharmaceutical composition of Factor VII polypeptides
JP5518282B2 (en)	2003-09-01	2014-06-11	ノヴォノルディスクアー／エス	Stable peptide formulation
ES2229931B1 (en)	2003-10-03	2006-01-16	Grifols, S.A.	BILOGICALLY STABLE LIQUID COMPOSITION OF FVIII, FVW OR HUMAN FVIII / FVW COMPLEX.
EP1687428A1 (en)	2003-11-14	2006-08-09	Novo Nordisk A/S	Processes for making acylated insulin
US8338374B2 (en)	2003-12-23	2012-12-25	Pharmacia Corporation	Stable growth hormone liquid formulation
DE602005014962D1 (en)	2004-03-12	2009-07-30	Biodel Inc	INSULIN COMPOSITIONS WITH IMPROVED ACTIVE ABSORPTION
EP1750750B1 (en)	2004-06-01	2012-02-01	Ares Trading S.A.	Method of stabilizing proteins
DE602005022895D1 (en)	2004-08-12	2010-09-23	Schering Corp	STABLE PEGYLATED INTERFERON FORMULATION
PT1778723E (en)	2004-08-17	2013-01-25	Regeneron Pharma	Il-1 antagonist formulations
WO2006051103A2 (en)	2004-11-12	2006-05-18	Novo Nordisk A/S	Stable formulations of peptides
ES2391776T3 (en)	2004-11-22	2012-11-29	Novo Nordisk A/S	Soluble, stable formulations containing insulin with a protamine salt
CA2593112A1 (en)	2005-01-21	2006-07-27	Alza Corporation	Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
WO2006082204A1 (en) *	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
JP4808785B2 (en)	2005-12-28	2011-11-02	ノボ・ノルデイスク・エー／エス	Insulin composition and method for producing the composition
EP1991576B1 (en)	2006-02-27	2010-09-29	Novo Nordisk A/S	Insulin derivatives
WO2007121256A2 (en)	2006-04-12	2007-10-25	Biodel, Inc.	Rapid acting and long acting insulin combination formulations
MX2008014061A (en)	2006-05-09	2008-11-14	Novo Nordisk As	Insulin derivative.
US9034818B2 (en)	2007-06-13	2015-05-19	Novo Nordisk A/S	Pharmaceutical formulations comprising an insulin derivative
JP5241849B2 (en)	2007-11-16	2013-07-17	ノボ・ノルデイスク・エー／エス	Pharmaceutical composition comprising insulin and insulinotropic peptide
TWI451876B (en)	2008-06-13	2014-09-11	Lilly Co Eli	Pegylated insulin lispro compounds

2004
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/en active IP Right Grant
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/en not_active Expired - Lifetime
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/en not_active Expired - Lifetime
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en not_active Ceased
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/en active IP Right Grant
- 2004-07-22 PL PL09165072T patent/PL2107069T3/en unknown
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/en active Protection Beyond IP Right Term
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/en active
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/en unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/en unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/en unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/en active Active
- 2013-07-04 CY CY2013027C patent/CY2013027PI1/en unknown
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/en active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI1/en unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/en unknown
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
2018
- 2018-01-11 NO NO2018003C patent/NO2018003I1/en unknown
- 2018-01-11 NO NO2018002C patent/NO2018002I2/en unknown
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/en unknown
2024
- 2024-01-16 NO NO2024003C patent/NO2024003I1/en unknown
- 2024-01-16 NO NO2024004C patent/NO2024004I1/en unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I1/en unknown

Also Published As

Publication number	Publication date
NO2018002I2 (en)	2018-08-20
US20060183668A1 (en)	2006-08-17
EP2264065A3 (en)	2011-07-27
BE2013C038I2 (en)	2023-12-14
MXPA06001283A (en)	2006-04-11
US20100009899A1 (en)	2010-01-14
CY2013027I2 (en)	2024-09-20
NO2024004I1 (en)	2024-01-16
US20140349925A1 (en)	2014-11-27
LU92226I9 (en)	2018-11-19
AU2004261353A1 (en)	2005-02-10
BE2013C035I2 (en)	2023-12-14
FR13C0035I1 (en)	2013-08-09
CY2013029I2 (en)	2024-09-20
AU2010200497A1 (en)	2010-03-04
PL2107069T3 (en)	2013-06-28
NO2018002I1 (en)	2018-01-11
WO2005012347A3 (en)	2005-04-14
AU2010200497B2 (en)	2014-10-23
EP2264065A2 (en)	2010-12-22
CY2013027PI2 (en)	2015-11-04
US8828923B2 (en)	2014-09-09
LU92226I2 (en)	2015-04-29
RU2008152033A (en)	2010-07-10
EP2107069A3 (en)	2009-11-25
BRPI0413276B1 (en)	2020-03-03
NO2024003I1 (en)	2024-01-16
KR101159559B1 (en)	2012-06-26
AU2004261353B2 (en)	2009-12-10
NO340925B1 (en)	2017-07-17
IL172980A (en)	2013-10-31
EP1660531A2 (en)	2006-05-31
LU92213I2 (en)	2013-08-23
CY2013029I1 (en)	2024-09-20
BRPI0413276B8 (en)	2021-05-25
NO2018003I1 (en)	2018-01-11
RU2518460C2 (en)	2014-06-10
CA2531988C (en)	2016-06-28
WO2005012347A2 (en)	2005-02-10
LU92213I9 (en)	2018-11-19
KR20060132543A (en)	2006-12-21
CY1113850T1 (en)	2015-11-04
EP2107069A2 (en)	2009-10-07
FR13C0035I2 (en)	2014-03-07
EP2107069B1 (en)	2013-01-16
CY2013027PI1 (en)	2015-11-04
HUS1300033I1 (en)	2016-08-29
EP2264065B1 (en)	2017-03-08
NO20061026L (en)	2006-03-02
JP4463814B2 (en)	2010-05-19
CY2013029PI1 (en)	2015-11-04
CA2531988A1 (en)	2005-02-10
BRPI0413276A (en)	2006-10-10
IL172980A0 (en)	2006-06-11
FR13C0038I1 (en)	2013-08-09
JP2007523881A (en)	2007-08-23
CY2013027I1 (en)	2024-09-20
US7615532B2 (en)	2009-11-10

Publication	Publication Date	Title
CY2013027I2 (en)	2024-09-20	NEW INSULIN DERIVATIVES
ATE340782T1 (en)	2006-10-15	PIPERIDINEBENZENESULFONAMIDE DERIVATIVES
ATE352550T1 (en)	2007-02-15	CHINAZOLINE DERIVATIVES
CY2015036I2 (en)	2016-06-22	NEW OXAZOLIDINONE DERIVATIVES
ATE420066T1 (en)	2009-01-15	AMIDOACETONITRIL DERIVATIVES
DK2609947T3 (en)	2020-07-06	Plaster-like infusion set
IS8108A (en)	2005-10-31	New compounds
DE602004017700D1 (en)	2008-12-24	TRANSMUKOSEN ADMINISTRATION
DK1606277T3 (en)	2008-08-18	Imidazol-4-yl-ethynyl-pyridine derivatives
IS2656B (en)	2010-08-15	New besimidasol derivatives
DK2107069T3 (en)	2013-04-15	New insulin derivatives
EP1661594A4 (en)	2010-04-14	SYRINGE
DE602004019555D1 (en)	2009-04-02	HETEROCYCLIC 7-AMINOALKYLIDENYLCHINOLONE AND -NAPHTHYRIDONE
IS8228A (en)	2006-01-11	New acetidine compounds
DK1682129T3 (en)	2007-06-11	N-thiazol-2-ylbenzamide derivatives
DK1706373T3 (en)	2010-01-18	Amidoacetonitrile derivatives
IS8292A (en)	2006-02-09	New compounds
IS8045A (en)	2005-09-26	Purin-6-one derivatives
FI20021817A7 (en)	2004-04-15	Cannula
UA6623S (en)	2002-11-15	SYRINGE
FI20030224A0 (en)	2003-02-13	New pharmaceutical uses
SE0301797D0 (en)	2003-06-19	New use V
SE0300106D0 (en)	2003-01-16	New use
SE0302332D0 (en)	2003-08-29	New use I
IS8301A (en)	2006-02-14	New Fusic Acid Derivatives